Cite
HARVARD Citation
Querfeld, C. et al. (n.d.). PHASE 1/2 TRIAL OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) +/‐ LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: PRELIMINARY RESULTS OF PHASE 1 AND CORRELATIVE STUDIES. Hematological oncology. pp. 519-520. [Online].